Vancouver-based patient-driven pharmaceutical company focused on psilocybin treatments, prioritizing Veterans as a patient population with high unmet need for PTSD and depression. Its lead candidate APEX-52 is a GMP-certified synthetic psilocybin drug designed for take-home use, and the company dosed its first Veteran patient in a Health Canada-approved take-home psilocybin clinical trial. Apex holds a Health Canada Dealer's Licence.
Apex Labs News 11 articles
- Canadian Veteran Receives Approval for APEX’s Psilocybin Therapy Through Health Canada’s Special Access Program
- Apex Labs announces the appointment of Chief Medical Officer & Chief Commercial Officer
- Apex Labs Receives Approval for US-Based Secondary GMP Psilocybin Supplier by Health Canada
- Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin Clinical Trial by Health Canada
- Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin Clinical Trial by Health Canada
- Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial
- Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial
- Apex Labs Pioneers Take-Home Psychedelic Treatment
- Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial
- Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial
- Apex Labs Granted Approval for North America’s First Take Home Psilocybin Clinical Trial